Toward an enzyme/prodrug strategy for cancer gene therapy: Endogenous activation of carboxypeptidase A mutants by the PACE/furin family of propeptidases

Human Gene Therapy

Volumn 10, Issue 2, 1999, Pages 235-248

  Hamstra, Daniel A ^a   Rehemtulla, Alnawaz ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID COPOLYMER; CARBOXYPEPTIDASE A; DIHYDROFOLATE REDUCTASE; DRUG CARRIER; ENZYME; FOLIC ACID; FURIN; METHOTREXATE; MUTANT PROTEIN; PEPTIDASE; PEPTIDE; PHENYLALANINE; PRODRUG; SUBTILISIN; TRYPSIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER GENETICS; CATALYSIS; CELL STRAIN COS1; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG HALF LIFE; ENZYME ACTIVATION; ENZYME SUBSTRATE COMPLEX; ENZYME THERAPY; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; SQUAMOUS CELL CARCINOMA;

ANIMALS; BASE SEQUENCE; CARBOXYPEPTIDASES; CARBOXYPEPTIDASES A; CATALYTIC DOMAIN; CLONING, MOLECULAR; COS CELLS; DNA PRIMERS; ENZYME ACTIVATION; GENE THERAPY; MICE; MUTAGENESIS; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RECOMBINANT PROTEINS; SUBTILISINS; TUMOR CELLS, CULTURED;

EID: 0033585434     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950019020     Document Type: Article

References (46)

1. AGER, S.P., and HASS, G.M. (1977). Affinity chromotography of pancreatic carboxypeptidases using a carboxypeptidase inhibitor from potatoes as ligand. Anal. Biochem. 83, 285-295.
2. BRUZZANITI, A., GOODGE, K., JAY, P., TAVIAUX, S.A., LAM, M.H.C., BERTA, P., MARTIN, T.J., MOSELEY, J.M., and GILLESPIE, M.T. (1996). PC8 [corrected], a new member of the convertase family. Biochem. J. 314, 727-731.
3. CHEN, L., and WAXMAN, D.J. (1995). Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
4. CONNORS, T.A. (1995). The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702-709.
5. CONSTAM, D.B., CALFON, M., and ROBERTSON, E.J. (1996). SPC4, SPC6, and the novel protease SPC7 are coexpressed with bone morphogenetic proteins at distinct sites during embryogenesis. J. Cell Biol. 134, 181-191.
6. CULVER, K.W., RAM, Z., WALLBRIDGE, I.H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In-vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
7. DAVIES, M.V., and KAUFMAN, R.J. (1992). Internal translation initiation in the design of improved expression vectors. Curr. Opin. Biotechnol. 3, 512-517.
8. DEONARAIN, M.P., SPOONER, R.A., and EPENETOS, A.A. (1995). Genetic delivery of enzymes for cancer therapy. Gene Ther. 2, 235-244.
9. ENSMINGER, W.D. (1984). Clinical pharmacology of folate analogs. In Folate Antagonists as Therapeutic Agents, Vol. 2. F.M. Siotnak, J.J. Burchall, W.D. Ensminger, and J.A. Montgomery, eds. (Academic Press, Orlando, FL) pp. 133-159.
10. FREEMAN, S.M., ABBOUND, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
11. FICK, J., BARKER, F.G., DAZIN, P., WESTPHALE, E.M., BEYER, E.C., and ISRAEL, M.A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. U.S.A. 92, 11071-11075.
12. GARDELL, S.J., CRAIK, C.S., HILVERT, D., URDEA, M.S., and RUTTER, W.J. (1985). Site-directed mutagenesis shows that tyrosine 248 of carboxypeptidase A does not play a crucial role in catalysis. Nature (London) 317, 551-555.
13. GUASCH, A., COLL, M., AVILES, F.X., and HUBER, R. (1992). Three-dimensional structure of porcine pancreatic procarboxypeptidase A. J. Mol. Biol. 224, 141-157.
14. HUBER, B.E., RICHARDS, C.A., and KRENTISKY, T.A. (1991). Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 8039-8043.
15. HUBER, B.E., AUSTIN, E.A., RICHARDS, C.A., DAVIS, S.T., and GOOD, S.S. (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U.S.A. 91, 8302-8309.
16. HUGUCHI, R. (1990). Recombinant PCR. In PCR Protocols: A Guide to Methods and Applications. M.A. Innis, D.H. Gelfand, J.J. Snisky, and T.J. White, eds. (Academic Press, San Diego, CA) pp. 177-183.
17. KRAKOFF, I.H. (1987). The irrelevant toxicities of anticancer drugs. In Organ Directed Toxicities of Anticancer Drugs. M.P. Hacker, J.S. Lazo, and T.R. Tritton, eds. (Martinus Nijhoff, Boston) pp. 3-12.
18. KRAUSE, C.J., CAREY, T.E., OTT, R.W., HURBIS, C., McCLATCHEY, K.D., and REGEZI, J.A. (1981). Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch. Otolaryngol. 107, 703-710.
19. KUEFNER, U., LHORMANN, U., MONTEJANO, Y., VITOLS, K.S., and HUENNEKENS, F.M. (1989). Carboxypeptidase-mediated release of methrotrexate from methotrexate-α-peptides. Biochemistry 28, 2288-2297.
20. LAWRENCE, T.S., REHEMTULLA, A., EMILY, E.Y., WILSON, M., TROSKO, J.E., and STETSON, P.L. (1998). Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 58, 2588-2593.
21. MARAIS, R., SPOONER, R.A., LIGHT, Y., MARTIN, J., and SPRINGER, C.J. (1996). Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56, 4735-4742.
22. MEERABUX, J., YASPO, M.-L., ROEBROEK, A.J., VAN DE VEN, W.J.M., LISTER, A., and YOUNG, B.D. (1996). A new member of the proprotein convertase gene family (LPC) is located at a chromosome translocation breakpoint in lymphomas. Cancer Res. 56, 448-451.
23. MERINO, O.R., LINDBERG, R.D., and FLETCHER, G.H. (1977). An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 40, 145-151.
24. MESNIL, M., PICCOLI, C., TIRABY, G., WILLECKE, K., and YAMASAKI, H. (1996). Bystnader killing of cancer cells by herpes simplex virus thymidinekinase gene is mediated by connexins. Proc. Natl. Acad. Sci. U.S.A. 93, 1831-1835.
25. MOOLTEN, F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
26. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
27. OPPEZZO, O., VENTURA, S., BERGMAN, T., VENDRELL, J., JORNVALL, H., and AVILES, F.X. (1994). Procarboxypeptidase in rat pancrease: Overall characterization and comparison of the activation process. Eur. J. Biochem. 222, 55-63.
28. PERRON, M.J., and PAGE, M. (1996). Activation of methotrexate-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Br. J. Cancer 73, 281-287.
29. PETERSON, L.M., HOLMQUIST, B., and BETHUNE, J.L. (1982). A unique assay for carboxypeptidase A in human serum. Anal. Biochem. 125, 420-426.
30. PHILLIPS, M.A., and RUTTER, W.J. (1996). Role of the prodomain in folding and secretion of rat pancreatic carboxypeptidase A1. Biochemistry 35, 6771-6776.
31. QUINTO, C., QUIROGA, M., SWAIN, W.F., NIKOVITS, W.C., JR., STANDRING, D.N., PICTET, R.L., VALENZUELA, P., and RUTTER, W.J. (1982). Rat preprocarboxypeptidase A: cDNA sequence and preliminary characterization of the gene. Proc. Natl. Acad. Sci. U.S.A. 79, 31-35.
32. RAM, Z., CULVER, K.W., WALBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
33. REHEMTULLA, A., and KAUFMAN, R.J. (1992a). Mammalian propeptide processing enzymes. Curr. Opin. Biotechnol. 3, 560-565.
34. REHEMTULLA, A., and KAUFMAN, R.J. (1992b). Preferred sequence requirements for cleavage of pro-vWF by propeptide processing enzymes. Blood 79, 2349-2355.
35. REHEMTULLA, A., DORNER, A., and KAUFMAN, R.J. (1992). Regulation of PACE/furin processing: Requirement for a post endoplasmic reticulum compartment and autoproteolytic activation. Proc. Natl. Acad. Sci. U.S.A. 89, 8235-8239.
36. SAMBROOK, J., FRITSCH, E.F., and MAMATIS, T., eds. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed. (Cold Springs Harbor Laboratory Press, Cold Springs Harbor, NY).
37. SCHLOKAT, U., FISCHER, B.E., HERLITSCHKA, S., ANTOINE, G., PREININGER, A., MOHR, G., HIMMELSPACH, M., KISTNER, O., FALKNER, F.G., and DORNER, F. (1996). Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro. Biotechnol. Appl. Biochem. 24, 257-267.
38. SEGUNDO, B.S., MARTINEZ, M.C., VILANOVA, C.M., CUCHILLO, C.M., and AVILES, F.X. (1982). The severed activation segment of porcine pancreatic procarboxypeptidase A is a powerful inhibitor of the active enzyme. Biochim. Biophys. Acta 707, 74-80.
39. SEIDAH, N.G., HAMMELIN, J., MAMARBACHI, M., DONG, W., TADROS, H., MBIKAY, M., CHRETIEN, M., and DAY, R. (1996). cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U.S.A. 93, 3388-3393.
40. SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS. A., McMAHON, J., VISTICA, D., WARREN, J.T., BOKESCH, H., KENNEY, S., and BOYD, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112.
41. SMITH, G.K., BANKS, S., BLUMENKOPF, T.A., CORY, M., HUMPHREYS, J., LAETHAM, R.M., MILLER, J., MOXHAM, C.P., MULLIN, R., RAY, P.H., WALTON, L.M., and WOLFE, L.A. (1997). Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem. 272, 15804-15816.
42. SPRINGER, C.J., BAVETSIAS, V., JACKMAN, A.L., BOYLE, F.T., MARSHALL, D., PEDLEY, R.B., and BISSET, G.M. (1996). Prodrugs of thymidylate synthase inhibitors: Potential for antibody directed enzyme prodrug therapy (ADEPT) Anticancer Drug Design 11, 625-636.
43. TATTERSALL, M.H.N. (1984). Clinical utility of methotrexate in neoplastic disease. In Folate Antagonists as Therapeutic Agents, Vol. 2. F.M. Siotnak, J.J. Burchall, W.D. Ensminger, and J.A. Montgomery, eds. (Academic Press, Orlando, FL) pp. 166-189.
44. VENDRELL, J., CUCHILLO, C.M., and AVILES, F.X. (1990). The tryptic activation pathway of monomeric procarboxypeptidase A. J. Biol. Chem. 265, 6949-6953.
45. VITOLS, K.S., HAAG-ZEINO, B., BAER, T., MONTEJANO, Y.D., and HUENNEKENS, F.M. (1995). Methotrexate-alpha-phenylalanine: Optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res. 55, 478-480.
46. WYGODA, M.R., WILSON, M.R., DAVIS, M.A., TROSKO, J.E., REHEMTULLA, A., and LAWRENCE, T.S. (1997). Protection of herpes simplex virus thymidine kinase-transduced cells from gancyclovir-mediated cytotoxicity by bystander cells: The Good Samaritan effect. Cancer Res. 57, 1699-1703.